Omnicell Past Earnings Performance

Past criteria checks 0/6

Omnicell's earnings have been declining at an average annual rate of -27.9%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 10.2% per year.

Key information

-27.9%

Earnings growth rate

-29.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate10.2%
Return on equity-1.7%
Net Margin-1.8%
Next Earnings Update02 May 2024

Recent past performance updates

Recent updates

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Mar 28
An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29
Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Feb 23
Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell Is Building A Strong Moat

Feb 22

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Jan 15
Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Dec 25
Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Dec 06
Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Nov 10
Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Sep 06
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Aug 08
Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Jul 02
Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Jun 08
A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Apr 29
Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Apr 11
Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Mar 23
At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Feb 28
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

Jan 15
Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Jan 01
We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Nov 17
Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Nov 03
Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Omnicell launches Specialty Pharmacy Services

Oct 11

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Sep 30
Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Sep 15
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Aug 31
Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Omnicell reports Q2 earnings miss; reaffirms FY22 guidance and issues Q3 outlook

Aug 04

Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 41%?

Aug 03
Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 41%?

Omnicell Fails To Justify Inclusion In Long-Only, Equity-Focused Portfolio

Jul 21

We Ran A Stock Scan For Earnings Growth And Omnicell (NASDAQ:OMCL) Passed With Ease

Jun 27
We Ran A Stock Scan For Earnings Growth And Omnicell (NASDAQ:OMCL) Passed With Ease

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Jun 13
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell's (NASDAQ:OMCL) Returns On Capital Are Heading Higher

May 30
Omnicell's (NASDAQ:OMCL) Returns On Capital Are Heading Higher

These 4 Measures Indicate That Omnicell (NASDAQ:OMCL) Is Using Debt Safely

May 05
These 4 Measures Indicate That Omnicell (NASDAQ:OMCL) Is Using Debt Safely

With EPS Growth And More, Omnicell (NASDAQ:OMCL) Is Interesting

Mar 16
With EPS Growth And More, Omnicell (NASDAQ:OMCL) Is Interesting

What Is Omnicell, Inc.'s (NASDAQ:OMCL) Share Price Doing?

Mar 04
What Is Omnicell, Inc.'s (NASDAQ:OMCL) Share Price Doing?

Omnicell (NASDAQ:OMCL) Is Looking To Continue Growing Its Returns On Capital

Feb 20
Omnicell (NASDAQ:OMCL) Is Looking To Continue Growing Its Returns On Capital

Revenue & Expenses Breakdown
Beta

How Omnicell makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:OMCL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,147-2042893
30 Sep 231,186-3445497
30 Jun 231,235-2346397
31 Mar 231,268-18475101
31 Dec 221,2966479102
30 Sep 221,3094845396
30 Jun 221,2586143891
31 Mar 221,1997241283
31 Dec 211,1327838176
30 Sep 211,0708035469
30 Jun 219876032765
31 Mar 219143530665
31 Dec 208923229766
30 Sep 208913829870
30 Jun 209064929871
31 Mar 209246929870
31 Dec 198976129069
30 Sep 198605427467
30 Jun 198364826966
31 Mar 198073826664
31 Dec 187873825965
30 Sep 187725425864
30 Jun 187544824964
31 Mar 187474424567
31 Dec 177133124166
30 Sep 17688-123365
30 Jun 17678-623864
31 Mar 17670-924360
31 Dec 166961023058
30 Sep 16651823152
30 Jun 165991421046
31 Mar 165392418441
31 Dec 154853116535
30 Sep 154763216634
30 Jun 154633216432
31 Mar 154553116130
31 Dec 144413115628
30 Sep 144252814927
30 Jun 144072914526
31 Mar 143952714127
31 Dec 133812413927
30 Sep 133652313526
30 Jun 133552213025

Quality Earnings: OMCL is currently unprofitable.

Growing Profit Margin: OMCL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OMCL is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare OMCL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OMCL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).


Return on Equity

High ROE: OMCL has a negative Return on Equity (-1.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.